candesartan has been researched along with Heart Disease, Ischemic in 19 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to test the hypothesis that there are blood pressure independent CVD-risk differences between losartan and candesartan treatment in patients with hypertension without known CVD." | 7.76 | Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. ( Bodegard, J; Hasvold, P; Kjeldsen, SE; Olsson, U; Russell, D; Stålhammar, J, 2010) |
| "Pretreatment with imidapril (ACE inhibitor) and candesartan cilexitil (AT1 receptor antagonist) significantly prevented the increase in the phosphorylation of JAK1 at 120 min and STAT3 at 30 and 120 min." | 5.31 | Myocardial ischemia activates the JAK-STAT pathway through angiotensin II signaling in in vivo myocardium of rats. ( Beppu, S; Ishikura, F; Kobayashi, H; Omura, T; Takeuchi, K; Yoshikawa, J; Yoshiyama, M, 2001) |
| " The aim of this study was to test the hypothesis that there are blood pressure independent CVD-risk differences between losartan and candesartan treatment in patients with hypertension without known CVD." | 3.76 | Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. ( Bodegard, J; Hasvold, P; Kjeldsen, SE; Olsson, U; Russell, D; Stålhammar, J, 2010) |
| "The calcium antagonist felodipine, the lipid-peroxidation inhibitor H290/51, and the angiotensin II type 1 (AT1)-receptor antagonist candesartan all exert beneficial effects on myocardial ischemia/reperfusion injury." | 3.70 | Combination of a calcium antagonist, a lipid-peroxidation inhibitor, and an angiotensin AT1-receptor antagonist provides additive myocardial infarct size-limiting effect in pigs. ( Rydén, L; Shimizu, M; Sjöquist, PO; Wang, QD, 1999) |
| "Cardiac complications were defined as left ventricular hypertrophy (LVH) and ischemic heart disease (IHD)." | 1.35 | Effects of cardiac complications on cardiovascular events in Japanese high-risk hypertensive patients: subanalysis of the CASE-J trial. ( Fujimoto, A; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Ueshima, K; Yasuno, S, 2009) |
| " The authors established with an initial dose-response curve using escalating concentrations of CN that 10 nmol/L abrogated vasoconstriction induced by angiotensin II (0." | 1.31 | Increased AT2R protein expression but not increased apoptosis during cardioprotection induced by AT1R blockade. ( Jugdutt, BI; Kumar, D; Moudgil, R; Musat-Marcu, S; Xu, Y, 2002) |
| "Pretreatment with imidapril (ACE inhibitor) and candesartan cilexitil (AT1 receptor antagonist) significantly prevented the increase in the phosphorylation of JAK1 at 120 min and STAT3 at 30 and 120 min." | 1.31 | Myocardial ischemia activates the JAK-STAT pathway through angiotensin II signaling in in vivo myocardium of rats. ( Beppu, S; Ishikura, F; Kobayashi, H; Omura, T; Takeuchi, K; Yoshikawa, J; Yoshiyama, M, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (21.05) | 18.2507 |
| 2000's | 11 (57.89) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sakamoto, T | 1 |
| Ogawa, H | 1 |
| Nakao, K | 3 |
| Koide, S | 1 |
| Yamamoto, N | 1 |
| Shimomura, H | 1 |
| Matsumura, T | 1 |
| Oshima, S | 1 |
| Kikuta, K | 1 |
| Oka, H | 1 |
| Kimura, K | 1 |
| Matsui, K | 1 |
| Ueshima, K | 2 |
| Yasuno, S | 2 |
| Oba, K | 2 |
| Fujimoto, A | 2 |
| Ogihara, T | 2 |
| Saruta, T | 2 |
| Kjeldsen, SE | 1 |
| Stålhammar, J | 1 |
| Hasvold, P | 1 |
| Bodegard, J | 1 |
| Olsson, U | 1 |
| Russell, D | 1 |
| Tanaka, S | 1 |
| Fukumoto, T | 1 |
| Tawa, M | 1 |
| Kitada, K | 1 |
| Yamashita, N | 1 |
| Ohkita, M | 1 |
| Okamura, T | 1 |
| Matsumura, Y | 1 |
| Moudgil, R | 2 |
| Musat-Marcu, S | 1 |
| Xu, Y | 2 |
| Kumar, D | 1 |
| Jugdutt, BI | 2 |
| Richardt, D | 1 |
| Wolfrum, S | 1 |
| Büttner, C | 1 |
| Schäfer, U | 1 |
| Dendorfer, A | 1 |
| Kurz, T | 1 |
| Richardt, G | 1 |
| Higashikuni, Y | 1 |
| Sata, M | 1 |
| Nagai, R | 1 |
| Shimizu, M | 2 |
| Sjöquist, PO | 2 |
| Wang, QD | 2 |
| Rydén, L | 2 |
| Matoba, S | 1 |
| Tatsumi, T | 1 |
| Keira, N | 1 |
| Kawahara, A | 1 |
| Akashi, K | 1 |
| Kobara, M | 1 |
| Asayama, J | 1 |
| Nakagawa, M | 1 |
| Sharma, A | 1 |
| Singh, M | 1 |
| Kawabata, H | 4 |
| Ryomoto, T | 3 |
| Ishikawa, K | 4 |
| Balghith, M | 1 |
| Menon, V | 1 |
| Omura, T | 1 |
| Yoshiyama, M | 1 |
| Ishikura, F | 1 |
| Kobayashi, H | 1 |
| Takeuchi, K | 1 |
| Beppu, S | 1 |
| Yoshikawa, J | 1 |
| Hiura, N | 1 |
| Wakatsuki, T | 1 |
| Yamamoto, T | 1 |
| Nishikado, A | 1 |
| Oki, T | 1 |
| Ito, S | 1 |
| Nakagawa, K | 1 |
1 trial available for candesartan and Heart Disease, Ischemic
| Article | Year |
|---|---|
Rationale, design and baseline characteristics of a study to evaluate effects of candesartan on cardiovascular events after drug-eluting stent implantation in patients with ischemic heart disease.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Angiotensin II Type 1 Receptor Blockers; Be | 2013 |
18 other studies available for candesartan and Heart Disease, Ischemic
| Article | Year |
|---|---|
Effects of cardiac complications on cardiovascular events in Japanese high-risk hypertensive patients: subanalysis of the CASE-J trial.
Topics: Adrenergic Antagonists; Aged; Amlodipine; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Calciu | 2009 |
Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; F | 2010 |
Influence of coronary risk factors on coronary events in Japanese high-risk hypertensive patients. - Primary and secondary prevention of ischemic heart disease in a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) tria
Topics: Aged; Amlodipine; Antihypertensive Agents; Asian People; Benzimidazoles; Biphenyl Compounds; Coronar | 2011 |
Different effects of AT1 receptor antagonist and ET(A) receptor antagonist on ischemia-induced norepinephrine release in rat hearts.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrasentan; Benzimidazoles; Biphenyl Compounds; Di | 2012 |
Increased AT2R protein expression but not increased apoptosis during cardioprotection induced by AT1R blockade.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Apoptosis; Benzimidazoles; Biphe | 2002 |
Effect of ACE-inhibitor ramiprilat and AT1-receptor antagonist candesartan on cardiac norepinephrine release: comparison between ischemic and nonischemic conditions.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; | 2002 |
Reversible left ventricular hypertrophy after tako-tsubo-like cardiomyopathy.
Topics: Aged; Aspirin; Benzimidazoles; Biphenyl Compounds; Cardiomyopathy, Dilated; Chest Pain; Drug Therapy | 2005 |
Effects of the angiotensin AT1 receptor blocker candesartan on myocardial ischemic/reperfusion injury.
Topics: Angiotensin Receptor Antagonists; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Calcium | 1999 |
Cardioprotective effect of angiotensin-converting enzyme inhibition against hypoxia/reoxygenation injury in cultured rat cardiac myocytes.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti | 1999 |
Role of angiotensin in cardioprotective effect of ischemic preconditioning.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Coron | 1999 |
Combination of a calcium antagonist, a lipid-peroxidation inhibitor, and an angiotensin AT1-receptor antagonist provides additive myocardial infarct size-limiting effect in pigs.
Topics: Anesthesia; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Antioxidants; Benzim | 1999 |
Effect of angiotensin converting enzyme inhibitor and angiotensin II type 1 receptor antagonist on metabolism and contraction in ischemia-reperfused rabbit heart.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2000 |
Cardioprotection induced by AT1R blockade after reperfused myocardial infarction: association with regional increase in AT2R, IP3R and PKCepsilon proteins and cGMP.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Calcium Channels; Cyc | 2000 |
Myocardial ischemia activates the JAK-STAT pathway through angiotensin II signaling in in vivo myocardium of rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blotting, West | 2001 |
Role of cardiac ATP-sensitive K+ channels induced by angiotensin II type 1 receptor antagonist on metabolism, contraction and relaxation in ischemia-reperfused rabbit heart.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2001 |
Cardioprotection with angiotensin converting enzyme inhibitor and angiotensin II type 1 receptor antagonist is not abolished by nitric oxide synthase inhibitor in ischemia-reperfused rabbit hearts.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; | 2001 |
Effects of angiotensin II type 1 receptor antagonist (candesartan) in preventing fatal ventricular arrhythmias in dogs during acute myocardial ischemia and reperfusion.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Dogs; Heart Conductio | 2001 |
Effects of an HMG-CoA reductase inhibitor in combination with an ACE inhibitor or angiotensin II type 1 receptor antagonist on myocardial metabolism in ischemic rabbit hearts.
Topics: Adenosine Triphosphate; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2002 |